tnm002
mAbexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 25, 2020 (NCT04629131)
Timeline
Indications
Mechanism of action
- Clostridium tetaniImmunity, passive
Clostridium tetani immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05664750 | Phase 3 | Dec 31, 2022 | Guangzhou Trinomab Biotech Co., Ltd., Peking University |
| NCT06607380 | Phase 1 | Aug 13, 2022 | Guangzhou Trinomab Biotech Co., Ltd., Peking University |
| NCT05625477 | Phase 2 | Apr 18, 2022 | Guangzhou Trinomab Biotech Co., Ltd., Peking University |
| NCT05842798 | Phase 1 | Oct 15, 2021 | Guangzhou Trinomab Biotech Co., Ltd., Sun Yat-Sen University |
| NCT04629131 | Phase 1 | Nov 25, 2020 | Guangzhou Trinomab Biotech Co., Ltd., Scientia Clinical Research Limited Sydney, Tigermed Consulting Co., Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Trinomab Biotech Co., Ltd. | Government | 5 | 5 | 3 | 2020 |
| Peking University | Academic/Hospital | 3 | 0 | 3 | 2022 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1